Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
Morgan Stanley Maintains Equal-Weight on Exelixis, Lowers Price Target to $57
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
Forget clinical cash burns: Why Exelixis is up 38% since June
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Short Sellers Are Betting Against This Biotech Stock at All-Time Highs, But You Should Still Add it to Your Watchlist
Leerink Partners Maintains Market Perform on Exelixis, Raises Price Target to $58
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $78
Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)
Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
Exelixis (EXEL) Q3 2026 Earnings Call Transcript
TD Cowen Maintains Buy on Exelixis, Raises Price Target to $76
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $60
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $58
Truist Securities Maintains Hold on Exelixis, Raises Price Target to $60
Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $54
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.